March 27, 2019

DarioHealth Partners with Glytec on Outpatient Diabetes Management

The Dario® Blood Glucose Monitoring System will be made available to hospitals and health systems using Glytec’s virtual insulin titration service for outpatients with diabetes.

Global digital therapeutics innovator, DarioHealth Corp. (Nasdaq: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care. The agreement allows DarioHealth’s smart glucose meter (part of the Dario Blood Glucose Monitoring System) to transmit information to Glytec’s Glucommander™ Outpatient software-as-a-medical-device.

June 6, 2018

Glytec Adds Smart Meter to Growing Network of Connected Solution Partners

The iGlucose® Cell-Enabled Diabetes Care Solution from Smart Meter is now compatible with Glytec’s virtual insulin titration service.

For millions of patients with diabetes who’ve been unable to achieve their treatment goals, few programs have the potential to reduce A1C faster or more effectively than Glytec’s virtual insulin titration service. The innovative service harnesses the integration of Glytec’s Glucommander™ Outpatient software with multiple connected diabetes technologies and health information systems, including those for blood glucose measurement, insulin delivery, medical record keeping and patient communication, among others. The latest company to join Glytec’s network of connected solution partners is Smart Meter, LLC, maker of the iGlucose® Cell-Enabled Diabetes Care Solution, bringing timely, complete and accurate data to insulin titration.

February 15, 2018

Study Shows Computer-Guided Insulin Dosing Plus More Frequent Blood Glucose Testing Leads to Better Outcomes for Patients with Diabetes

New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.

A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

January 5, 2018

Glytec Awarded Patent Allowance Supporting Connected Care Model for Insulin Management

The allowed patent encompasses detailed interactions between multiple connected diabetes technologies.

Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient environment. The new patent allowance comprises 30 individual claims describing a connected care model that harnesses the integration of Glytec’s software-as-a-medical-device for insulin titration with multiple current- and future-state connected diabetes technologies and health information systems, including any and all devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.

November 29, 2017

Glytec Integrates With Onduo Virtual Diabetes Clinic

The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.

Glytec is pleased to announce its Glucommander™ Outpatient will be integrated with Onduo’s virtual diabetes clinic to help people with type 2 diabetes more easily manage insulin therapy and achieve their glucose targets. Onduo, a joint venture of Sanofi and Verily (an Alphabet company), is developing a virtual platform that integrates hardware, such as wirelessly-connected continuous glucose monitors, software and personalized support from healthcare experts to help people manage their type 2 diabetes. The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.

September 19, 2017

New Research Shows People on Insulin For Diabetes Maintain A1C Reductions Through Digital Therapy Management

A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.

More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.

July 24, 2017

Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities

Data-sharing capabilities are important for faster communications and results that can greatly benefit the patient, says Robby Booth, senior vice president of research and development at Glytec.

Over the past few months, there have been some announcements that we’ve made. We have a partnership now with AgaMatrix, which is a Bluetooth glucose meter, to be able to capture their data from the cloud. We have a partnership with Livongo, which is a cellular meter, so we can capture that data from their cloud; and we have a partnership with Telcare, which is also a cellular meter.

April 18, 2017

Livongo Partnership With Glytec Supports Members and Their Providers With Insulin Titration

Livongo goes deeper into medication optimization.

Livongo Health, the leading consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives, today announced a partnership with Glytec to offer eGlycemic Management System®, or eGMS®, to Livongo members. With this alliance, Livongo and Glytec will partner to deliver an expanded diabetes management solution that includes insulin titration, making managing diabetes easier for members and their providers.

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

June 16, 2016

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

November 9, 2015

Glucose Management by Software Proves Effective

A software system called Glucommander from Glytec Systems works well at titrating the right dose to bring blood sugar levels under control.

The company has now released results of a 30-day study for outpatients using the system in their homes. The subjects were given a glucometer that transmits data readings using a cellular data connection. The Glucommander system would then send the recommended dosage to the patient as a text message. The results of the test showed that 90% of the subjects in the study were able to achieve their target levels within three weeks.

November 3, 2015

Study of Glytec’s Glucommander in an Outpatient Setting Indicates Dramatic A1C Reductions

Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.

Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes. According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%.